Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates.

Suschak JJ, Schmaljohn CS.

Hum Vaccin Immunother. 2019 Oct 7:1-19. doi: 10.1080/21645515.2019.1651140. [Epub ahead of print]

PMID:
31589088
2.

Persistent Crimean-Congo hemorrhagic fever virus infection in the testes and within granulomas of non-human primates with latent tuberculosis.

Smith DR, Shoemaker CJ, Zeng X, Garrison AR, Golden JW, Schellhase CW, Pratt W, Rossi F, Fitzpatrick CJ, Shamblin J, Kimmel A, Zelko J, Flusin O, Koehler JW, Liu J, Coffin KM, Ricks KM, Voorhees MA, Schoepp RJ, Schmaljohn CS.

PLoS Pathog. 2019 Sep 26;15(9):e1008050. doi: 10.1371/journal.ppat.1008050. eCollection 2019 Sep.

3.

GP38-targeting monoclonal antibodies protect adult mice against lethal Crimean-Congo hemorrhagic fever virus infection.

Golden JW, Shoemaker CJ, Lindquist ME, Zeng X, Daye SP, Williams JA, Liu J, Coffin KM, Olschner S, Flusin O, Altamura LA, Kuehl KA, Fitzpatrick CJ, Schmaljohn CS, Garrison AR.

Sci Adv. 2019 Jul 10;5(7):eaaw9535. doi: 10.1126/sciadv.aaw9535. eCollection 2019 Jul.

4.

Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques.

Jiang J, Banglore P, Cashman KA, Schmaljohn CS, Schultheis K, Pugh H, Nguyen J, Humeau LM, Broderick KE, Ramos SJ.

Hum Vaccin Immunother. 2019;15(9):2066-2074. doi: 10.1080/21645515.2019.1616499. Epub 2019 Jun 19.

5.

Development of a bead-based immunoassay using virus-like particles for detection of alphaviral humoral response.

Ricks KM, Shoemaker CJ, Dupuy LC, Flusin O, Voorhees MA, Fulmer AN, Badger CV, Schmaljohn CS, Schoepp RJ.

J Virol Methods. 2019 Aug;270:12-17. doi: 10.1016/j.jviromet.2019.04.013. Epub 2019 Apr 15.

PMID:
30998959
6.

Self-Amplifying RNA Vaccines for Venezuelan Equine Encephalitis Virus Induce Robust Protective Immunogenicity in Mice.

Samsa MM, Dupuy LC, Beard CW, Six CM, Schmaljohn CS, Mason PW, Geall AJ, Ulmer JB, Yu D.

Mol Ther. 2019 Apr 10;27(4):850-865. doi: 10.1016/j.ymthe.2018.12.013. Epub 2019 Jan 7.

PMID:
30770173
7.

Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses.

Hulseberg CE, Fénéant L, Szymańska-de Wijs KM, Kessler NP, Nelson EA, Shoemaker CJ, Schmaljohn CS, Polyak SJ, White JM.

J Virol. 2019 Apr 3;93(8). pii: e02185-18. doi: 10.1128/JVI.02185-18. Print 2019 Apr 15.

8.

Immune-Mediated Systemic Vasculitis as the Proposed Cause of Sudden-Onset Sensorineural Hearing Loss following Lassa Virus Exposure in Cynomolgus Macaques.

Cashman KA, Wilkinson ER, Zeng X, Cardile AP, Facemire PR, Bell TM, Bearss JJ, Shaia CI, Schmaljohn CS.

MBio. 2018 Oct 30;9(5). pii: e01896-18. doi: 10.1128/mBio.01896-18.

9.

The genetic adjuvant IL-12 enhances the protective efficacy of a DNA vaccine for Venezuelan equine encephalitis virus delivered by intramuscular injection in mice.

Suschak JJ, Bagley K, Six C, Shoemaker CJ, Kwilas S, Spik KW, Dupuy LC, Schmaljohn CS.

Antiviral Res. 2018 Nov;159:113-121. doi: 10.1016/j.antiviral.2018.09.014. Epub 2018 Sep 27.

PMID:
30268913
10.

The Genetic Adjuvants Interleukin-12 and Granulocyte-Macrophage Colony Stimulating Factor Enhance the Immunogenicity of an Ebola Virus Deoxyribonucleic Acid Vaccine in Mice.

Suschak JJ, Bagley K, Shoemaker CJ, Six C, Kwilas S, Dupuy LC, Schmaljohn CS.

J Infect Dis. 2018 Nov 22;218(suppl_5):S519-S527. doi: 10.1093/infdis/jiy378.

PMID:
30053157
12.

DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs.

Cashman KA, Wilkinson ER, Wollen SE, Shamblin JD, Zelko JM, Bearss JJ, Zeng X, Broderick KE, Schmaljohn CS.

Hum Vaccin Immunother. 2017 Dec 2;13(12):3010-3019. doi: 10.1080/21645515.2017.1382780. Epub 2017 Nov 14.

13.

A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever.

Cashman KA, Wilkinson ER, Shaia CI, Facemire PR, Bell TM, Bearss JJ, Shamblin JD, Wollen SE, Broderick KE, Sardesai NY, Schmaljohn CS.

Hum Vaccin Immunother. 2017 Dec 2;13(12):2902-2911. doi: 10.1080/21645515.2017.1356500. Epub 2017 Oct 18.

14.

Protocols to Assess Coagulation Following In Vitro Infection with Hemorrhagic Fever Viruses.

Tursiella ML, Taylor SL, Schmaljohn CS.

Methods Mol Biol. 2018;1604:405-417. doi: 10.1007/978-1-4939-6981-4_30.

PMID:
28986851
15.

Future Approaches to DNA Vaccination Against Hemorrhagic Fever Viruses.

Suschak JJ, Schmaljohn CS.

Methods Mol Biol. 2018;1604:339-348. doi: 10.1007/978-1-4939-6981-4_26.

PMID:
28986847
16.

Intracellular Detection of Viral Transcription and Replication Using RNA FISH.

Lindquist ME, Schmaljohn CS.

Methods Mol Biol. 2018;1604:201-207. doi: 10.1007/978-1-4939-6981-4_14.

PMID:
28986835
17.

A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models.

Garrison AR, Shoemaker CJ, Golden JW, Fitzpatrick CJ, Suschak JJ, Richards MJ, Badger CV, Six CM, Martin JD, Hannaman D, Zivcec M, Bergeron E, Koehler JW, Schmaljohn CS.

PLoS Negl Trop Dis. 2017 Sep 18;11(9):e0005908. doi: 10.1371/journal.pntd.0005908. eCollection 2017 Sep.

18.

Epitope mapping of Ebola virus dominant and subdominant glycoprotein epitopes facilitates construction of an epitope-based DNA vaccine able to focus the antibody response in mice.

Mitchell DAJ, Dupuy LC, Sanchez-Lockhart M, Palacios G, Back JW, Shimanovskaya K, Chaudhury S, Ripoll DR, Wallqvist A, Schmaljohn CS.

Hum Vaccin Immunother. 2017 Dec 2;13(12):2883-2893. doi: 10.1080/21645515.2017.1347740. Epub 2017 Jul 12.

19.

Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity.

Suschak JJ, Williams JA, Schmaljohn CS.

Hum Vaccin Immunother. 2017 Dec 2;13(12):2837-2848. doi: 10.1080/21645515.2017.1330236. Epub 2017 Jun 12. Review.

20.

An immunoinformatics-derived DNA vaccine encoding human class II T cell epitopes of Ebola virus, Sudan virus, and Venezuelan equine encephalitis virus is immunogenic in HLA transgenic mice.

Bounds CE, Terry FE, Moise L, Hannaman D, Martin WD, De Groot AS, Suschak JJ, Dupuy LC, Schmaljohn CS.

Hum Vaccin Immunother. 2017 Dec 2;13(12):2824-2836. doi: 10.1080/21645515.2017.1329788. Epub 2017 Jun 2.

21.

Biosafety standards for working with Crimean-Congo hemorrhagic fever virus.

Weidmann M, Avsic-Zupanc T, Bino S, Bouloy M, Burt F, Chinikar S, Christova I, Dedushaj I, El-Sanousi A, Elaldi N, Hewson R, Hufert FT, Humolli I, Jansen van Vuren P, Koçak Tufan Z, Korukluoglu G, Lyssen P, Mirazimi A, Neyts J, Niedrig M, Ozkul A, Papa A, Paweska J, Sall AA, Schmaljohn CS, Swanepoel R, Uyar Y, Weber F, Zeller H.

J Gen Virol. 2016 Nov;97(11):2799-2808. doi: 10.1099/jgv.0.000610. Epub 2016 Sep 19.

PMID:
27667586
22.

Meeting report: Tenth International Conference on Hantaviruses.

Papa A, Vaheri A, LeDuc JW, Krüger DH, Avšič-Županc T, Arikawa J, Song JW, Markotić A, Clement J, Liang M, Li D, Yashina LN, Jonsson CB, Schmaljohn CS.

Antiviral Res. 2016 Sep;133:234-41. doi: 10.1016/j.antiviral.2016.08.015. Epub 2016 Aug 17.

23.

Mapping of Ebolavirus Neutralization by Monoclonal Antibodies in the ZMapp Cocktail Using Cryo-Electron Tomography and Studies of Cellular Entry.

Tran EE, Nelson EA, Bonagiri P, Simmons JA, Shoemaker CJ, Schmaljohn CS, Kobinger GP, Zeitlin L, Subramaniam S, White JM.

J Virol. 2016 Aug 12;90(17):7618-27. doi: 10.1128/JVI.00406-16. Print 2016 Sep 1.

24.

A Phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation.

Hannaman D, Dupuy LC, Ellefsen B, Schmaljohn CS.

Vaccine. 2016 Jun 30;34(31):3607-12. doi: 10.1016/j.vaccine.2016.04.077. Epub 2016 May 17.

PMID:
27206386
25.

Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.

Bounds CE, Kwilas SA, Kuehne AI, Brannan JM, Bakken RR, Dye JM, Hooper JW, Dupuy LC, Ellefsen B, Hannaman D, Wu H, Jiao JA, Sullivan EJ, Schmaljohn CS.

PLoS One. 2015 Sep 30;10(9):e0137786. doi: 10.1371/journal.pone.0137786. eCollection 2015.

26.

Rift Valley fever virus NSS gene expression correlates with a defect in nuclear mRNA export.

Copeland AM, Van Deusen NM, Schmaljohn CS.

Virology. 2015 Dec;486:88-93. doi: 10.1016/j.virol.2015.09.003. Epub 2015 Sep 25.

27.

Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges.

Grant-Klein RJ, Altamura LA, Badger CV, Bounds CE, Van Deusen NM, Kwilas SA, Vu HA, Warfield KL, Hooper JW, Hannaman D, Dupuy LC, Schmaljohn CS.

Hum Vaccin Immunother. 2015;11(8):1991-2004. doi: 10.1080/21645515.2015.1039757.

28.

A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skin.

McCoy JR, Mendoza JM, Spik KW, Badger C, Gomez AF, Schmaljohn CS, Sardesai NY, Broderick KE.

Hum Vaccin Immunother. 2015;11(3):746-54. doi: 10.4161/21645515.2014.978223.

29.

A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skin.

McCoy JR, Mendoza JM, Spik KW, Badger C, Gomez AF, Schmaljohn CS, Sardesai NY, Broderick KE.

Hum Vaccin Immunother. 2014;10(10):3039-47. doi: 10.4161/hv.29671. Epub 2014 Nov 21.

30.

Discovery of a novel compound with anti-venezuelan equine encephalitis virus activity that targets the nonstructural protein 2.

Chung DH, Jonsson CB, Tower NA, Chu YK, Sahin E, Golden JE, Noah JW, Schroeder CE, Sotsky JB, Sosa MI, Cramer DE, McKellip SN, Rasmussen L, White EL, Schmaljohn CS, Julander JG, Smith JM, Filone CM, Connor JH, Sakurai Y, Davey RA.

PLoS Pathog. 2014 Jun 26;10(6):e1004213. doi: 10.1371/journal.ppat.1004213. eCollection 2014 Jun.

31.

Current strategic thinking for the development of a trivalent alphavirus vaccine for human use.

Wolfe DN, Heppner DG, Gardner SN, Jaing C, Dupuy LC, Schmaljohn CS, Carlton K.

Am J Trop Med Hyg. 2014 Sep;91(3):442-50. doi: 10.4269/ajtmh.14-0055. Epub 2014 May 19.

32.

Discovery of hantaviruses and of the Hantavirus genus: personal and historical perspectives of the Presidents of the International Society of Hantaviruses.

Lee HW, Vaheri A, Schmaljohn CS.

Virus Res. 2014 Jul 17;187:2-5. doi: 10.1016/j.virusres.2013.12.019. Epub 2014 Jan 8.

PMID:
24412711
33.

DNA vaccines for HFRS: laboratory and clinical studies.

Schmaljohn CS, Spik KW, Hooper JW.

Virus Res. 2014 Jul 17;187:91-6. doi: 10.1016/j.virusres.2013.12.020. Epub 2013 Dec 24.

PMID:
24370868
34.

A fusion-inhibiting peptide against Rift Valley fever virus inhibits multiple, diverse viruses.

Koehler JW, Smith JM, Ripoll DR, Spik KW, Taylor SL, Badger CV, Grant RJ, Ogg MM, Wallqvist A, Guttieri MC, Garry RF, Schmaljohn CS.

PLoS Negl Trop Dis. 2013 Sep 12;7(9):e2430. doi: 10.1371/journal.pntd.0002430. eCollection 2013.

35.

Nuclear relocalization of polyadenylate binding protein during rift valley fever virus infection involves expression of the NSs gene.

Copeland AM, Altamura LA, Van Deusen NM, Schmaljohn CS.

J Virol. 2013 Nov;87(21):11659-69. doi: 10.1128/JVI.01434-13. Epub 2013 Aug 21.

36.

Endothelial cell permeability during hantavirus infection involves factor XII-dependent increased activation of the kallikrein-kinin system.

Taylor SL, Wahl-Jensen V, Copeland AM, Jahrling PB, Schmaljohn CS.

PLoS Pathog. 2013;9(7):e1003470. doi: 10.1371/journal.ppat.1003470. Epub 2013 Jul 18.

37.

Crimean-Congo hemorrhagic fever virus utilizes a clathrin- and early endosome-dependent entry pathway.

Garrison AR, Radoshitzky SR, Kota KP, Pegoraro G, Ruthel G, Kuhn JH, Altamura LA, Kwilas SA, Bavari S, Haucke V, Schmaljohn CS.

Virology. 2013 Sep;444(1-2):45-54. doi: 10.1016/j.virol.2013.05.030. Epub 2013 Jun 19.

38.

IFITM-2 and IFITM-3 but not IFITM-1 restrict Rift Valley fever virus.

Mudhasani R, Tran JP, Retterer C, Radoshitzky SR, Kota KP, Altamura LA, Smith JM, Packard BZ, Kuhn JH, Costantino J, Garrison AR, Schmaljohn CS, Huang IC, Farzan M, Bavari S.

J Virol. 2013 Aug;87(15):8451-64. doi: 10.1128/JVI.03382-12. Epub 2013 May 29.

39.

Enhanced Efficacy of a Codon-Optimized DNA Vaccine Encoding the Glycoprotein Precursor Gene of Lassa Virus in a Guinea Pig Disease Model When Delivered by Dermal Electroporation.

Cashman KA, Broderick KE, Wilkinson ER, Shaia CI, Bell TM, Shurtleff AC, Spik KW, Badger CV, Guttieri MC, Sardesai NY, Schmaljohn CS.

Vaccines (Basel). 2013 Jul 18;1(3):262-77. doi: 10.3390/vaccines1030262.

40.

Construction and nonclinical testing of a Puumala virus synthetic M gene-based DNA vaccine.

Brocato RL, Josleyn MJ, Wahl-Jensen V, Schmaljohn CS, Hooper JW.

Clin Vaccine Immunol. 2013 Feb;20(2):218-26. doi: 10.1128/CVI.00546-12. Epub 2012 Dec 12.

41.

A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from ebola and Marburg virus challenge.

Grant-Klein RJ, Van Deusen NM, Badger CV, Hannaman D, Dupuy LC, Schmaljohn CS.

Hum Vaccin Immunother. 2012 Nov 1;8(11):1703-6. doi: 10.4161/hv.21873. Epub 2012 Aug 24.

42.

Military vaccines in today's environment.

Schmaljohn CS, Smith LA, Friedlander AM.

Hum Vaccin Immunother. 2012 Aug;8(8):1126-8. doi: 10.4161/hv.20503. Epub 2012 Aug 1.

43.

Vaccines for hantaviruses: progress and issues.

Schmaljohn CS.

Expert Rev Vaccines. 2012 May;11(5):511-3. doi: 10.1586/erv.12.15. No abstract available.

PMID:
22827236
44.

Recommendations for publication of viral genetic data and sample access for novel viruses and strains.

Arrigo NC, Briese T, Calisher CH, Drebot MA, Hjelle B, LeDuc JW, Powers AM, Repik PM, Roehrig JT, Schmaljohn CS, Tesh RB, Weaver SC.

Am J Trop Med Hyg. 2012 Feb;86(2):189-91. doi: 10.4269/ajtmh.2012.11-0523. No abstract available.

45.

Novel plant-derived recombinant human interferons with broad spectrum antiviral activity.

Koehler JW, Dupuy LC, Garrison AR, Beitzel BF, Richards MJ, Ripoll DR, Wallqvist A, Teh SY, Vaewhongs AA, Vojdani FS, Padgett HS, Schmaljohn CS.

Antiviral Res. 2011 Dec;92(3):461-9. doi: 10.1016/j.antiviral.2011.10.008. Epub 2011 Oct 14.

PMID:
22020161
46.

Progress in recombinant DNA-derived vaccines for Lassa virus and filoviruses.

Grant-Klein RJ, Altamura LA, Schmaljohn CS.

Virus Res. 2011 Dec;162(1-2):148-61. doi: 10.1016/j.virusres.2011.09.005. Epub 2011 Sep 10. Review.

PMID:
21925552
47.

A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates.

Dupuy LC, Richards MJ, Ellefsen B, Chau L, Luxembourg A, Hannaman D, Livingston BD, Schmaljohn CS.

Clin Vaccine Immunol. 2011 May;18(5):707-16. doi: 10.1128/CVI.00030-11. Epub 2011 Mar 30.

48.

Development and application of a flow cytometric potency assay for DNA vaccines.

Badger CV, Richardson JD, Dasilva RL, Richards MJ, Josleyn MD, Dupuy LC, Hooper JW, Schmaljohn CS.

Vaccine. 2011 Sep 9;29(39):6728-35. doi: 10.1016/j.vaccine.2010.12.053. Epub 2011 Jan 8.

PMID:
21219978
49.

High-resolution functional mapping of the venezuelan equine encephalitis virus genome by insertional mutagenesis and massively parallel sequencing.

Beitzel BF, Bakken RR, Smith JM, Schmaljohn CS.

PLoS Pathog. 2010 Oct 14;6(10):e1001146. doi: 10.1371/journal.ppat.1001146.

50.

Immunogenicity and protective efficacy of a DNA vaccine against Venezuelan equine encephalitis virus aerosol challenge in nonhuman primates.

Dupuy LC, Richards MJ, Reed DS, Schmaljohn CS.

Vaccine. 2010 Oct 28;28(46):7345-50. doi: 10.1016/j.vaccine.2010.09.005. Epub 2010 Sep 17.

PMID:
20851089

Supplemental Content

Loading ...
Support Center